iwCAR-T 2022 | Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…

Following a fantastic day at the 4th International Workshop on CAR-T (iwCAR-T) 2022 in Tampa, FL, leading experts David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle, WA, John Gribben, MD, DSc, FRCPath, FMed Sci, Barts and The London School of Medicine, Queen Mary University of London, London, UK, and Noelle Frey, MD, MSCE, University of Pennsylvania, Philadelphia, PA, share their highlights from the leukemia and lymphoma sessions. To begin with, the experts discuss the past, present, and future of CAR-T therapy in acute lymphoblastic leukemia (ALL), outlining strategies to improve relapse-free survival (RFS) in these patients. They then comment on the key challenges to CAR-T therapy in acute myeloid leukemia (AML) and highlight recent progress in this field. Finally, Dr Maloney, Dr Frey, and Prof. Gribben provide an overview of recent advances in CAR-T therapy for chronic lymphocytic leukemia (CLL), discussing the potential of ibrutinib in modulating the immune microenvironment and improving T-cell fitness in both CLL and in lymphoma, and emphasize the importance of determining the optimal window of opportunity for CAR-T in CLL.